MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, ATRA has $19,997K in assets. $57,309K in debts. $8,360K in cash and cash equivalents.

Balance Sheets Overview

Current Ratio
215.64%
Quick Ratio
215.64%
Cash Ratio
148.10%
Debt to Asset Ratio
286.59%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Operating lease assets
    • Other current assets
    • Others
Liabilities Breakdown
    • Accumulated deficit
    • Additional paid-in capital
    • Liability related to the sale of...
    • Others

Balance Sheets
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Inventories
-0 0 0
Cash and cash equivalents
8,360 8,482 5,742 16,903
Short-term investments
-0 7,970 5,420
Restricted cash
-0 0 0
Accounts receivable
0 1,253 1,913 0
Other current assets
3,813 2,477 2,807 2,449
Total current assets
12,173 12,212 18,432 24,772
Property and equipment, gross
-286 551 -
Less accumulated depreciation and amortization
-213 404 -
Property and equipment, net
55 73 147 176
Operating lease assets
6,879 7,064 10,707 11,027
Other assets
890 886 881 927
Total assets
19,997 20,235 30,167 36,902
Accounts payable
637 127 318 1,762
Accrued compensation
629 1,271 2,067 2,552
Accrued research and development expenses
41 82 342 971
Deferred revenue
684 716 1,011 1,607
Liability related to the sale of future revenues - current portion
715 9,750 9,670 -
Other current liabilities
2,939 2,976 4,649 7,671
Total current liabilities
5,645 14,922 18,057 14,563
Operating lease liabilities - long-term
9,076 9,347 15,005 15,426
Deferred revenue - long-term
---0
Liability related to the sale of future revenues - long-term
40,759 32,673 31,976 40,222
Other long-term liabilities
1,829 1,795 1,763 1,732
Total liabilities
57,309 58,737 66,801 71,943
Common stock - 0.0001 par value, 500,000 shares authorized as of march 31, 2026 and december 31, 2025 8,512 and 7,324 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively
1 1 1 1
Additional paid-in capital
1,988,697 1,983,361 1,981,822 1,979,114
Accumulated other comprehensive income (loss)
0 1 2 0
Accumulated deficit
-2,026,010 -2,021,865 -2,018,459 -2,014,156
Total stockholders' equity (deficit)
-37,312 -38,502 -36,634 -35,041
Total liabilities and stockholders' equity (deficit)
19,997 20,235 30,167 36,902
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$8,360K Other current assets$3,813K Total current assets$12,173K Operating lease assets$6,879K Other assets$890K Property and equipment,net$55K Total assets$19,997K Accumulated deficit-$2,026,010K Total liabilities andstockholders' equity...$19,997K Total stockholders'equity (deficit)-$37,312K Additional paid-in capital$1,988,697K Common stock - 0.0001par value, 500,000...$1K Total liabilities$57,309K Liability related to thesale of future...$40,759K Operating leaseliabilities - long-term$9,076K Total currentliabilities$5,645K Other long-termliabilities$1,829K Other currentliabilities$2,939K Liability related to thesale of future...$715K Deferred revenue$684K Accounts payable$637K Accrued compensation$629K Accrued research anddevelopment expenses$41K

Atara Biotherapeutics, Inc. (ATRA)

Atara Biotherapeutics, Inc. (ATRA)